MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, FULC had $4,486K increase in cash & cash equivalents over the period. -$14,280K in free cash flow.

Cash Flow Overview

Change in Cash
$4,486K
Free Cash flow
-$14,280K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net (loss) income
-19,595 -34,951
Depreciation expense
346 697
Stock-based compensation expense
3,360 6,042
Net accretion of discounts on marketable securities
586 1,984
Unbilled accounts receivable
0 -2,096
Prepaid expenses and other current assets
-44 -1,544
Operating lease assets and liabilities
195 353
Other assets
-3 2
Accounts payable
946 587
Accrued expenses and other liabilities
1,487 -2,753
Net cash (used in) provided by operating activities
-14,190 -29,077
Purchases of marketable securities
17,293 136,790
Maturities of marketable securities
35,995 150,011
Purchases of property and equipment
90 65
Net cash provided by investing activities
18,612 13,156
Proceeds from issuance of common stock under benefit plans, net
64 301
Net cash provided by financing activities
64 301
Net (decrease) increase in cash, cash equivalents and restricted cash
4,486 -15,620
Cash and cash equivalents at beginning of period
59,413 -
Cash and cash equivalents at end of period
48,279 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. (FULC)